Position in MDXG
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$456,055
+$78,866 QoQ
Shares Held
118,456
+24.0% QoQ
Ownership
0.081%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#69
of 226 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MDXG Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026AVIVA PLC holds $284,688,734 across 21 Biotechnology names. MDXG ranks #16 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
223,593 | $111,065,350 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
91,486 | $57,045,180 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
114,532 | $34,477,567 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
118,070 | $22,112,149 | |
| 5 | RPRX |
Royalty Pharma plc
|
359,125 | $20,136,138 | |
| 6 | INCY |
Incyte Corp
|
148,924 | $16,882,024 | |
| 7 | INSM |
INSMED Inc
|
144,131 | $15,367,247 | |
| 8 | LEGN |
Legend Biotech Corp
|
53,486 | $1,544,675 |
All Filings in MDXG
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $456,055 | 118,456 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $377,189 | 95,491 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $482,254 | 71,234 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $474,800 | 68,023 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $444,881 | 72,812 | Shares | Defined | 2025-08-07 | |
| 2025-03-31 | $586,416 | 77,160 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $628,628 | 65,346 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $602,695 | 101,979 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $595,529 | 85,935 | Shares | Defined | 2024-08-02 | |
| 2024-03-31 | $207,499 | 26,948 | Shares | Defined | 2024-05-14 | |
| No filing history on record for this holder in this stock. | ||||||